RNUGF News Alert Reneuron Group Plc (RNUGF) 0.0370 02/15/2015
Post# of 64074
Posted On: 02/15/2015 11:59:47 AM
Reneuron Group Plc (RNUGF) 0.0370 $RNUGF
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), PSTI: 2.91 (+0.01), OSIR: 15.95 (+0.28), OPXA: 0.71 (-0.03), FCSC: 4.75 (+0.50), BAX: 70.39 (+0.31), CYTX: 0.47 (unch)
Critical Limb Ischemia - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/m55nsq/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences - AnGes MG - Apceth GmbH & Co - Athersys - Hemostemix - Human Stem Cells Institute - Juventas Therapeutics - Kasiak Research - Multi Gene Vascular Systems - NeoStem - Nuo Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron Group - Stempeutics Research Private - TikoMed - ViroMed For more information visit http://www.researchandmarkets.com/research/m5...tical_limb
PSTI: 2.91 (+0.01)
Northwest Biotherapeutics: Capital Raise Of $35 Million Could Be A Positive Catalyst For The Stock
Smith On Stocks - Seeking Alpha - Thu Nov 20, 10:21AM CST
$35 Million Capital Raise Strengthens Balance Sheet Northwest Biotherapeutics (NASDAQ: NWBO ) announced after the market close on November 19th that it had completed a deal with the United Kingdom money manager Woodford Equity Income Fund to raise...
NWBO: 6.07 (+0.13)
ReNeuron's (RNUGF) CEO Olav Hellebo on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 18, 2:28PM CST
ReNeuron Group plc - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:55AM CDT
Summary
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rtp9gn/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - AstraZeneca PLC - Athersys, Inc. - CardioVascular BioTherapeutics, Inc. - Sigma-Tau S.p.A. - Celgene Corporation - Cytokinetics, Incorporated - Cytomedix, Inc. - ReNeuron Group plc - Genovate Biotechnology Co., LTD. - Proteon Therapeutics, Inc. - Diffusion Pharmaceuticals LLC - Theravasc, Inc. - ViroMed Co., Ltd. - DNAVEC Corporation - miRagen Therapeutics, Inc. - RegenoCELL Therapeutics, Inc. - Provasculon, Inc. - Multi Gene Vascular Systems Ltd - Cardiolynx AG - Exodos Life Science Limited - Recardio GmbH For more information visit http://www.researchandmarkets.com/research/rtp9gn/peripheral
CYTK: 7.78 (+1.29), AZN: 69.96 (+0.20), ATHX: 2.12 (unch), CELGZ: 3.17 (-0.04)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), PSTI: 2.91 (+0.01), OSIR: 15.95 (+0.28), OPXA: 0.71 (-0.03), FCSC: 4.75 (+0.50), BAX: 70.39 (+0.31), CYTX: 0.47 (unch)
Critical Limb Ischemia - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/m55nsq/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences - AnGes MG - Apceth GmbH & Co - Athersys - Hemostemix - Human Stem Cells Institute - Juventas Therapeutics - Kasiak Research - Multi Gene Vascular Systems - NeoStem - Nuo Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron Group - Stempeutics Research Private - TikoMed - ViroMed For more information visit http://www.researchandmarkets.com/research/m5...tical_limb
PSTI: 2.91 (+0.01)
Northwest Biotherapeutics: Capital Raise Of $35 Million Could Be A Positive Catalyst For The Stock
Smith On Stocks - Seeking Alpha - Thu Nov 20, 10:21AM CST
$35 Million Capital Raise Strengthens Balance Sheet Northwest Biotherapeutics (NASDAQ: NWBO ) announced after the market close on November 19th that it had completed a deal with the United Kingdom money manager Woodford Equity Income Fund to raise...
NWBO: 6.07 (+0.13)
ReNeuron's (RNUGF) CEO Olav Hellebo on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 18, 2:28PM CST
ReNeuron Group plc - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:55AM CDT
Summary
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rtp9gn/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - AstraZeneca PLC - Athersys, Inc. - CardioVascular BioTherapeutics, Inc. - Sigma-Tau S.p.A. - Celgene Corporation - Cytokinetics, Incorporated - Cytomedix, Inc. - ReNeuron Group plc - Genovate Biotechnology Co., LTD. - Proteon Therapeutics, Inc. - Diffusion Pharmaceuticals LLC - Theravasc, Inc. - ViroMed Co., Ltd. - DNAVEC Corporation - miRagen Therapeutics, Inc. - RegenoCELL Therapeutics, Inc. - Provasculon, Inc. - Multi Gene Vascular Systems Ltd - Cardiolynx AG - Exodos Life Science Limited - Recardio GmbH For more information visit http://www.researchandmarkets.com/research/rtp9gn/peripheral
CYTK: 7.78 (+1.29), AZN: 69.96 (+0.20), ATHX: 2.12 (unch), CELGZ: 3.17 (-0.04)
(0)
(0)Scroll down for more posts ▼